NEW YORK, April 22, 2015 /PRNewswire/ -- Spectrum Pharmaceuticals, Inc. (NASDAQ: SPPI) is a California based commercial-stage biotechnology company with fully integrated commercial and drug development operations, and a focus in oncology and hematology recently announced results of a clinical study of the stability of Captisol-enabled Melphalan versus the currently marketed, propylene glycol-containing melphalan formulation entitled, 'Solution Stability of Captisol-enabled Melphalan vs Marketed Melphalan Products'. This is but one of the company's products that has a diversified portfolio of commercial, late-stage and early-stage development stage products.
Data from the study show that EVOMELA has significantly better stability in solution compared to the marketed melphalan formulations. Reconstituted solution in vials is 17X more stable, and the admixture solution in bags is 5X more stable, respectively, than the same solutions prepared using currently marketed formulations.
For a more detailed research report with analyst comments and recommendation on Spectrum Pharmaceuticals, Inc. please follow the link. There is no cost obligation required to view analyst brief.
Copy and paste to browser may be required.
This report was prepared for informational purposes only. Affiliated parties involved with producing and issuing this report have not been compensated in any form by profiled company. A full disclaimer can be found by viewing the full analyst report.
This report may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the Safe Harbor created by those sections. This material contains statements about expected future events and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward-looking statements by definition involve risks, uncertainties and other factors, which may cause the actual results, performance or achievements of mentioned company to be materially different from the statements made herein.
Content is researched, written and reviewed on a best-effort basis. This document, article or report is written and authored by Robert Borowski, research analyst. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below. We do not engage in high frequency trading.
BrokerBank Securities, Inc. is a member of the Financial Industry Regulatory Authority, CRD number #130116.
SOURCE BrokerBank Securities, Inc.